CL2015003346A1 - Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas - Google Patents
Composiciones de cenicriviroc y métodos para realizarlas y utilizarlasInfo
- Publication number
- CL2015003346A1 CL2015003346A1 CL2015003346A CL2015003346A CL2015003346A1 CL 2015003346 A1 CL2015003346 A1 CL 2015003346A1 CL 2015003346 A CL2015003346 A CL 2015003346A CL 2015003346 A CL2015003346 A CL 2015003346A CL 2015003346 A1 CL2015003346 A1 CL 2015003346A1
- Authority
- CL
- Chile
- Prior art keywords
- making
- methods
- cenicriviroc
- composition
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 title abstract 2
- 229950011033 cenicriviroc Drugs 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823766P | 2013-05-15 | 2013-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015003346A1 true CL2015003346A1 (es) | 2016-09-16 |
Family
ID=51898872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015003346A CL2015003346A1 (es) | 2013-05-15 | 2015-11-13 | Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160081985A1 (enExample) |
| EP (1) | EP2996694A4 (enExample) |
| JP (1) | JP6391674B2 (enExample) |
| KR (1) | KR20160013068A (enExample) |
| CN (1) | CN105263498B (enExample) |
| AU (1) | AU2014265327B2 (enExample) |
| BR (1) | BR112015028644A2 (enExample) |
| CA (1) | CA2911212A1 (enExample) |
| CL (1) | CL2015003346A1 (enExample) |
| IL (1) | IL242394B (enExample) |
| MX (1) | MX383706B (enExample) |
| MY (1) | MY180145A (enExample) |
| PH (1) | PH12015502539B1 (enExample) |
| RU (1) | RU2633069C2 (enExample) |
| SG (2) | SG10201708595YA (enExample) |
| UA (1) | UA115807C2 (enExample) |
| WO (1) | WO2014186581A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003014105A1 (en) | 2001-08-08 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use as hiv inhibitors |
| KR20160132489A (ko) * | 2014-03-21 | 2016-11-18 | 토비라 쎄라퓨틱스, 인크. | 섬유증 치료용 세니크리바이록 |
| US20170319548A1 (en) * | 2014-09-12 | 2017-11-09 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| US10526349B2 (en) | 2014-12-23 | 2020-01-07 | Tobira Therapeutics, Inc. | Process of making cenicriviroc and related analogs |
| US20180110754A1 (en) * | 2015-02-10 | 2018-04-26 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of fibrosis |
| WO2016135740A1 (en) * | 2015-02-23 | 2016-09-01 | Natco Pharma Limited | Process for preparing stable oral compositions of everolimus |
| RU2018113437A (ru) * | 2015-09-16 | 2019-10-17 | Тобира Терапьютикс, Инк. | Комбинированная терапия с использованием ценикривирока для лечения фиброза |
| MX2018015871A (es) | 2016-06-21 | 2019-08-14 | Tobira Therapeutics Inc | Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc. |
| EP3496718A4 (en) | 2016-08-08 | 2020-01-22 | Hetero Labs Limited | ANTIRETROVIRAL COMPOSITIONS |
| CN110167550A (zh) | 2016-08-31 | 2019-08-23 | 妥必徕疗治公司 | 西克里维罗甲磺酸盐的固体形式及其制备方法 |
| US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
| SG11201910191RA (en) | 2017-05-11 | 2019-11-28 | Univ King Abdullah Sci & Tech | A peptide capable of forming a gel for use in tissue engineering and bioprinting |
| KR102418307B1 (ko) | 2017-05-11 | 2022-07-06 | 킹 압둘라 유니버시티 오브 사이언스 앤드 테크놀로지 | 미세유체공학-기반 3d 바이오프린팅용 장치 및 방법 |
| RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
| US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| WO2021133811A1 (en) * | 2019-12-26 | 2021-07-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of cenicriviroc and process for preparation thereof |
| WO2021148992A1 (en) * | 2020-01-23 | 2021-07-29 | Lupin Limited | Pharmaceutical compositions of raltegravir |
| US11673324B2 (en) | 2020-08-20 | 2023-06-13 | King Abdullah University Of Science And Technology | Nozzle for 3D bioprinting |
| US12109327B2 (en) | 2020-08-20 | 2024-10-08 | King Abdullah University Of Science And Technology | Scaffolds from self-assembling tetrapeptides support 3D spreading, osteogenic differentiation and angiogenesis of mesenchymal stem cells |
| JP2022108727A (ja) * | 2021-01-13 | 2022-07-26 | 日曹商事株式会社 | フマル酸含有固形製剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2167649C2 (ru) * | 1995-08-11 | 2001-05-27 | Ниссан Кемикал Индастриз, Лтд. | Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция |
| US6297244B1 (en) * | 1997-10-20 | 2001-10-02 | Dainippon Pharmaceutical Co., Ltd. | Stable drug composition |
| CA2244097A1 (en) * | 1998-08-21 | 2000-02-21 | Bernard Charles Sherman | Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid |
| WO2000061109A1 (fr) * | 1999-04-12 | 2000-10-19 | Shionogi & Co., Ltd. | Procede de production de composition medicamenteuse renfermant un compose medicamenteux hydrophobe basique |
| WO2006059716A1 (ja) * | 2004-12-03 | 2006-06-08 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| CA2794443A1 (en) * | 2010-04-02 | 2011-10-06 | Phivco-1 Llc | Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer |
| KR20160132489A (ko) * | 2014-03-21 | 2016-11-18 | 토비라 쎄라퓨틱스, 인크. | 섬유증 치료용 세니크리바이록 |
-
2014
- 2014-05-15 JP JP2016514093A patent/JP6391674B2/ja not_active Expired - Fee Related
- 2014-05-15 BR BR112015028644A patent/BR112015028644A2/pt not_active Application Discontinuation
- 2014-05-15 KR KR1020157035069A patent/KR20160013068A/ko not_active Ceased
- 2014-05-15 SG SG10201708595YA patent/SG10201708595YA/en unknown
- 2014-05-15 MY MYPI2015703958A patent/MY180145A/en unknown
- 2014-05-15 EP EP14797645.0A patent/EP2996694A4/en not_active Withdrawn
- 2014-05-15 US US14/891,019 patent/US20160081985A1/en not_active Abandoned
- 2014-05-15 CN CN201480027717.3A patent/CN105263498B/zh active Active
- 2014-05-15 MX MX2015015500A patent/MX383706B/es unknown
- 2014-05-15 WO PCT/US2014/038211 patent/WO2014186581A1/en not_active Ceased
- 2014-05-15 AU AU2014265327A patent/AU2014265327B2/en not_active Ceased
- 2014-05-15 UA UAA201512359A patent/UA115807C2/uk unknown
- 2014-05-15 SG SG11201509136YA patent/SG11201509136YA/en unknown
- 2014-05-15 CA CA2911212A patent/CA2911212A1/en not_active Abandoned
- 2014-05-15 RU RU2014150327A patent/RU2633069C2/ru active
-
2015
- 2015-11-02 IL IL242394A patent/IL242394B/en active IP Right Grant
- 2015-11-05 PH PH12015502539A patent/PH12015502539B1/en unknown
- 2015-11-13 CL CL2015003346A patent/CL2015003346A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201509136YA (en) | 2015-12-30 |
| JP6391674B2 (ja) | 2018-09-19 |
| JP2016518452A (ja) | 2016-06-23 |
| AU2014265327B2 (en) | 2019-08-15 |
| MX2015015500A (es) | 2016-08-11 |
| NZ713981A (en) | 2021-03-26 |
| CN105263498A (zh) | 2016-01-20 |
| CN105263498B (zh) | 2019-04-26 |
| RU2633069C2 (ru) | 2017-10-11 |
| PH12015502539A1 (en) | 2016-02-22 |
| UA115807C2 (uk) | 2017-12-26 |
| WO2014186581A1 (en) | 2014-11-20 |
| KR20160013068A (ko) | 2016-02-03 |
| CA2911212A1 (en) | 2014-11-20 |
| EP2996694A1 (en) | 2016-03-23 |
| US20160081985A1 (en) | 2016-03-24 |
| MX383706B (es) | 2025-03-14 |
| HK1214171A1 (zh) | 2016-07-22 |
| SG10201708595YA (en) | 2017-11-29 |
| RU2014150327A (ru) | 2016-07-10 |
| MY180145A (en) | 2020-11-23 |
| PH12015502539B1 (en) | 2016-02-22 |
| BR112015028644A2 (pt) | 2017-07-25 |
| IL242394B (en) | 2019-05-30 |
| AU2014265327A1 (en) | 2015-11-26 |
| EP2996694A4 (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015003346A1 (es) | Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas | |
| CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
| CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| BR112017002811A2 (pt) | compostos de pirrolopirimidina usados como agonista de tlr7 | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CL2016001150A1 (es) | Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas. | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CL2015000543A1 (es) | Derivados de alcanediil y alcanediil-c17, de ácido oleanólico compuestos intermediarios, composición parmacéutica y métodos asociados. | |
| DOP2016000253A (es) | Nuevos compuestos | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| CL2017000715A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo | |
| MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
| CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| BR112016028316A2 (pt) | composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento | |
| CL2017000707A1 (es) | Derivados de nucleosidos sustituidos de 4'-vinilo como inhibidores de la replicación del arn del virus sincicial respiratorio | |
| EA201790495A1 (ru) | Фармацевтические композиции длительного действия | |
| MX2017004312A (es) | Composicion farmaceutica oral de baja dosis de isotretinoina. | |
| MX2017002737A (es) | Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio. | |
| PE20160596A1 (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt |